The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

Mersana to collaborate with Merck KGaA to develop ADCs

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Mersana Therapeutics Inc. and a subsidiary of Merck KGaA in Darmstadt, Germany, formed a research collaboration and commercial license agreement to discover novel Immunosynthen antibody-drug conjugates directed against up to two targets.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Lifileucel + pembrolizumab show promise for advanced melanoma in data from phase II study

Iovance Biotherapeutics Inc. a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, has updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, for the upcoming 2024 ASCO Annual Meeting. 
Clinical Roundup

Enhertu improves PFS in HR-positive, HER2-low breast cancer in phase III trial

Positive high-level results from the DESTINY-Breast06 phase III trial showed that Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account